Literature DB >> 9645368

The antigen presentation pathway in medullary thymic epithelial cells, but not that in cortical thymic epithelial cells, conforms to the endocytic pathway.

M Kasai1, E Kominami, T Mizuochi.   

Abstract

Murine medullary thymic epithelial cells (mTEC), but not cortical thymic epithelial cells (cTEC), are able to present a soluble antigen, ovalbumin, to helper T cells (Mizuochi, T. et al., J. Exp. Med. 1992. 175: 1601-1605). This functional difference between the mTEC and the cTEC is particularly important when we consider the thymic selection of the T cell repertoire. In the previous report, we proposed that mTEC and cTEC utilize two distinct antigen processing/presenting pathways (Kasai, M. et al., Eur. J. Immunol. 1996. 26: 2101-2107). In this report, we further confirmed this difference by analyzing (a) localization of MHC class II, H2-DM, and invariant chain (li) molecules, (b) the biochemical nature of MHC class II molecules, (c) the sensitivity of MHC class II alphabeta heterodimer formation to concanamycin A, a vacuolar H+-ATPase inhibitor, and (d) the subcellular distribution of MHC class II, H2-DM, and li molecules, in both TEC. Our results demonstrated that, in the mTEC, MHC class II, H2-DM and li molecules gain access to the endocytic pathway, where the luminal condition is acidic and thus li molecules are efficiently degraded and H2-DM molecules function well. In the cTEC, however, such molecules seemed to gain access to an alternative transport pathway, e.g. a secretory pathway, where the luminal condition is not fully acidic. These two distinct antigen processing pathways may account for the functional difference between mTEC and cTEC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645368     DOI: 10.1002/(SICI)1521-4141(199806)28:06<1867::AID-IMMU1867>3.0.CO;2-K

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice.

Authors:  Paula R Menges; Scott A Jenks; Elizabeth K Bikoff; David R Friedmann; Zackery A G Knowlden; Andrea J Sant
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 3.  Autophagy in T-cell development, activation and differentiation.

Authors:  Alisha W Bronietzki; Marc Schuster; Ingo Schmitz
Journal:  Immunol Cell Biol       Date:  2014-10-07       Impact factor: 5.126

4.  Prss16 is not required for T-cell development.

Authors:  Saijai Cheunsuk; Zhe-Xiong Lian; Guo-Xiang Yang; M Eric Gershwin; Jeffrey R Gruen; Christopher L Bowlus
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

5.  Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.

Authors:  Eva Tolosa; Weijie Li; Yoshiyuki Yasuda; Wolfgang Wienhold; Lisa K Denzin; Alfred Lautwein; Christoph Driessen; Petra Schnorrer; Ekkehard Weber; Stefan Stevanovic; Raffael Kurek; Arthur Melms; Dieter Bromme
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 6.  Modes of Antigen Presentation by Lymph Node Stromal Cells and Their Immunological Implications.

Authors:  Sachiko Hirosue; Juan Dubrot
Journal:  Front Immunol       Date:  2015-09-08       Impact factor: 7.561

Review 7.  Thymic and Postthymic Regulation of Naïve CD4(+) T-Cell Lineage Fates in Humans and Mice Models.

Authors:  José E Belizário; Wesley Brandão; Cristiano Rossato; Jean Pierre Peron
Journal:  Mediators Inflamm       Date:  2016-05-30       Impact factor: 4.711

8.  Lack of the MHC class II chaperone H2-O causes susceptibility to autoimmune diseases.

Authors:  Robin A Welsh; Nianbin Song; Catherine A Foss; Tatiana Boronina; Robert N Cole; Scheherazade Sadegh-Nasseri
Journal:  PLoS Biol       Date:  2020-02-18       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.